Field Treatment for Sun Damage Looks Worst at the Moment It's Working

The one treatment where looking worse is the point

Almost everything in skincare is judged by whether it avoids visible irritation. Field therapy for actinic keratoses inverts that entirely. The cream is supposed to make the treated area red, sore, crusted and — around the second week — genuinely difficult to look at. That reaction is the drug finding cells with damaged DNA and destroying them. A course that produces nothing much to see has usually produced nothing much at all.

Which creates a predictable failure. Somebody is handed a tube with instructions to apply it twice daily for a few weeks, is told there may be "some redness," and by day ten has a face that looks scalded. Nobody warned them it would go this far. They stop, wash it off, and conclude the treatment was too harsh — at exactly the point in the course where stopping wastes the discomfort already endured without collecting the benefit.

The honest framing is that this is a two-to-three week project with a visible middle, not a cream you fold into a morning routine. Knowing the shape of it in advance is what makes it survivable. Knowing why it has to happen makes it worth surviving.

Why treating the lesion you can see misses the point

The rough, scaly patches you can feel with a fingertip are the visible fraction of a much larger problem. Decades of ultraviolet exposure mutate keratinocytes across a whole region of skin — the scalp, the forehead, the backs of the hands — and only some of those mutated clones have grown enough to be palpable. That is field cancerisation, and it is why freezing four spots on a scalp can be both a correct treatment and an incomplete one.

The numbers make the trade-off unusually clear. In a long-running study that mapped and tracked 7,784 individual actinic keratoses on the faces and ears of 169 high-risk participants, the risk of any one lesion progressing to a squamous cell carcinoma was 0.60% at one year and 2.57% at four years. Read alone, that sounds like grounds for ignoring them. But the same study found that roughly 65% of the primary squamous cell carcinomas in the cohort arose at sites previously diagnosed clinically as an actinic keratosis — and that most individual lesions came and went, with 55% no longer present at the one-year check.

Both facts are true at once, and together they explain the whole strategy. Individual lesions are unreliable predictors: most regress, and the one that matters is not identifiable in advance. The person carrying dozens of them is at meaningful risk even though each spot is not. So the sensible target is the field rather than the lesion — treat the region, accept that most of what you destroy would have resolved anyway, and reduce the number of chances the field gets.

What the options actually deliver, head to head

For years the choice between field treatments was made on habit and tolerability rather than comparative data. That changed with a Dutch randomized trial published in the New England Journal of Medicine in 2019, which put four approaches against each other in patients with multiple lesions on the head and followed them for a year after treatment ended.

The results were not close. The cumulative probability of remaining free from treatment failure at 12 months was 74.7% for 5% fluorouracil cream, 53.9% for 5% imiquimod, 37.7% for methyl aminolevulinate photodynamic therapy, and 28.9% for ingenol mebutate gel. Fluorouracil — the oldest, cheapest and least glamorous option on the list — beat everything else by a wide margin, and it is a useful corrective to the assumption that a procedure performed in a clinic must outperform a cream applied at home.

Ingenol mebutate has since left the story altogether. It had been marketed on a genuinely attractive premise, a course lasting two or three days rather than weeks, but European regulators suspended it in January 2020 and its marketing authorisation was withdrawn the following month after trial data showed more skin cancers in treated areas than with the comparator — 6.3% of patients against 2% over three years, driven mainly by squamous cell carcinoma. The convenience was real and it was not worth it.

None of this makes fluorouracil automatically correct for a given person. Photodynamic therapy compresses the reaction into a supervised session and suits people who cannot manage weeks of home application; imiquimod recruits the immune system and behaves differently on different people; cryotherapy remains the right answer for a small number of discrete lesions on an otherwise unremarkable background. The point is that when the field is the problem, the evidence favours the unfashionable cream.

The reaction, in the order it arrives

For a typical fluorouracil course, the first few days are uneventful enough to be worrying — nothing appears to be happening. Toward the end of the first week the treated area reddens, and the redness is not uniform: it concentrates on the abnormal cells, which means patches you never knew existed light up alongside the ones you could feel. People frequently report that the reaction revealed more damage than they thought they had. That map is diagnostic information, not a treatment error.

Through the second week the reaction intensifies into erosion and crusting. This is the phase that ends courses: it is sore, it looks alarming, and it is socially conspicuous on a face or a bald scalp. It is also the phase that is doing the work, and it is followed — once application stops — by roughly one to two weeks of healing, during which the crusting lifts and the new skin underneath is pink and smooth. Imiquimod runs a similar arc on a less predictable schedule, and can bring flu-like symptoms with it; photodynamic therapy front-loads the whole thing into stinging during the illumination and an intense few days afterwards.

What helps is deliberately boring. During the reaction, strip the routine to a bland cleanser such as Vanicream Gentle Facial Cleanser and a plain occlusive like Aquaphor Healing Ointment to keep the eroded areas from drying into tight crusts, applied around the treatment schedule your clinician set rather than instead of it. Everything active comes out of the routine for the duration — no acids, no retinoids, no scrubs, no vitamin C. Sun exposure during the reaction is genuinely counterproductive, since the skin is inflamed and photosensitive at the same time.

The things worth phoning about are specific rather than general: spreading pain that keeps getting worse after the course ends, honey-coloured crusting or pus that suggests infection, fever, or an eye that becomes involved. Being ugly on day twelve is not on that list. Photographing the area daily — the Photo Tracker exists for precisely this — turns a frightening fortnight into a sequence you can watch progressing, and gives your clinician something better than a memory to review afterwards.

Adherence is not a side issue. It is the outcome.

The efficacy figures from trials describe people who finished the course under supervision. Ordinary practice looks different. In a cross-sectional study of 113 patients with a median age of 78.5, non-adherence to self-applied topical treatment ran to 46.9%, and only 30.9% used the treatment as the product information specified. The patients who deviated were significantly less likely to have been told how long the application period was, and they adjusted both the duration and the frequency on their own initiative. The patients who reported an adequate pre-treatment conversation were the ones who followed it.

A qualitative study of people who had used fluorouracil and then declined ever to repeat it found the same theme from the other direction: the reaction was physically and socially burdensome, and most participants did not feel their clinician had prepared them for what was coming. The treatment did not fail them. The briefing did.

That is worth taking seriously because the payoff is documented. In a randomized, placebo-controlled trial in veterans with a history of keratinocyte carcinoma, a single conventional course of 5% fluorouracil applied to the face and ears reduced surgically treated squamous cell carcinoma over the following year by 75% — five patients in the treatment arm against twenty on vehicle. The effect faded after that first year, which is an argument for repeating courses periodically rather than an argument against doing one.

So plan the course like an event. Start it when you have a fortnight without a wedding, a conference or a holiday in it. Tell the people you live with what it will look like. Put the completion date in a calendar so the finish line is a date rather than a judgement made in the mirror on a bad morning. And if the reaction becomes unmanageable, the conversation is with your clinician about pausing or adjusting — not a unilateral stop that leaves the field half-treated.

The lesion that doesn't clear, and the field that keeps producing

Roughly two to three months after the skin has healed is when the course gets assessed, and the assessment is not "does it look better." It is whether any individual lesion is still there. A patch that survived a full field treatment has demonstrated something about itself: persistent, thickened, tender, ulcerated or growing lesions warrant a biopsy rather than another cream, because that is how an invasive squamous cell carcinoma announces itself among a field of keratoses. Tenderness is a particularly useful signal, since ordinary actinic keratoses are usually more rough than sore.

Be clear about what home checking can and cannot do here. The ABCDE rules are a melanoma tool built around pigmented lesions, and applying them to a scaly pink patch will reassure you about the wrong thing — use the ABCDE Check for moles and treat any persistent keratotic lesion as a separate question for a clinician. The Skin Cancer Risk tool is the more relevant one for this population, because it frames how often the whole field needs looking at rather than judging one spot.

And then the part that never ends: the field remains a field. Treatment clears what is there; it does not remove the accumulated ultraviolet damage that produced it, which is why courses get repeated over the years and why daily photoprotection stops being cosmetic advice and becomes part of the treatment plan. For skin that has just been through a field course, a mineral filter such as Blue Lizard Sensitive Mineral Sunscreen SPF 50+ or a lightweight zinc formula like EltaMD UV Clear SPF 46 tends to be better tolerated on healing skin than a heavier organic-filter lotion, and on a bald or thinning scalp a hat outperforms every product ever formulated. Our ↗actinic keratosis pathway sets out how the escalation from cryotherapy to field therapy to specialist referral is actually staged, once you know which problem you are treating.